Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1993 May 22;306(6889):1367–1373. doi: 10.1136/bmj.306.6889.1367

Cholesterol lowering and mortality: the importance of considering initial level of risk.

G D Smith 1, F Song 1, T A Sheldon 1
PMCID: PMC1677836  PMID: 8518602

Abstract

OBJECTIVE--To investigate the level of risk of death from coronary heart disease above which cholesterol lowering treatment produces net benefits. DESIGN--Meta-analysis of results of randomised controlled trials of cholesterol lowering treatments. METHODS--Published and unpublished data from all identified randomised controlled trials of cholesterol lowering treatments with six months or more follow up and with at least one death were included in the meta-analysis. The analyses were stratified by the rate of death from coronary heart disease in the control arms of the trials. MAIN OUTCOME MEASURES--Death from all causes, from coronary heart disease, and from causes other than coronary heart disease. RESULTS--In the pooled analysis, net benefit in terms of total mortality from cholesterol lowering was seen only for trials including patients at very high initial risk of coronary heart disease (odds ratio 0.74; 95% confidence interval 0.60 to 0.92). In a medium risk group no net effect was seen, and in the low risk group there were adverse treatment effects (1.22; 1.06 to 1.42). In a weighted regression analysis a significant (p < 0.001) trend of increasing benefit with increasing initial risk of coronary heart disease was shown. Raised mortality from causes other than coronary heart disease was seen in trials of drug treatment (1.21; 1.05 to 1.39) but not in the trials of non-drug treatments (1.02; 0.88 to 1.19). Cumulative meta-analysis showed that these results seem to have been stable as new trials appeared. CONCLUSION--Currently evaluated cholesterol lowering drugs seem to produce mortality benefits in only a small proportion of patients at very high risk of death from coronary heart disease. Population cholesterol screening could waste resources and even result in net harm in substantial groups of patients. Overall risk of coronary heart disease should be the main focus of clinical guidelines, and a cautious approach to the use of cholesterol lowering drugs should be advocated. Future trials should aim to clarify the level of risk above which treatment is of net benefit.

Full text

PDF
1368

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acheson J., Hutchinson E. C. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis. 1972 Mar-Apr;15(2):177–183. doi: 10.1016/0021-9150(72)90067-6. [DOI] [PubMed] [Google Scholar]
  2. Berlin J. A., Laird N. M., Sacks H. S., Chalmers T. C. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989 Feb;8(2):141–151. doi: 10.1002/sim.4780080202. [DOI] [PubMed] [Google Scholar]
  3. Betteridge D. J. Blood cholesterol: who to test. 2. Br J Hosp Med. 1992 May 6;47(9):643–644. [PubMed] [Google Scholar]
  4. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  5. Bradford R. H., Shear C. L., Chremos A. N., Dujovne C., Downton M., Franklin F. A., Gould A. L., Hesney M., Higgins J., Hurley D. P. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991 Jan;151(1):43–49. doi: 10.1001/archinte.151.1.43. [DOI] [PubMed] [Google Scholar]
  6. Brand R., Kragt H. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Stat Med. 1992 Dec;11(16):2077–2082. doi: 10.1002/sim.4780111605. [DOI] [PubMed] [Google Scholar]
  7. Brensike J. F., Levy R. I., Kelsey S. F., Passamani E. R., Richardson J. M., Loh I. K., Stone N. J., Aldrich R. F., Battaglini J. W., Moriarty D. J. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984 Feb;69(2):313–324. doi: 10.1161/01.cir.69.2.313. [DOI] [PubMed] [Google Scholar]
  8. Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J. T., Kaplan C., Zhao X. Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 Nov 8;323(19):1289–1298. doi: 10.1056/NEJM199011083231901. [DOI] [PubMed] [Google Scholar]
  9. Buchwald H., Varco R. L., Matts J. P., Long J. M., Fitch L. L., Campbell G. S., Pearce M. B., Yellin A. E., Edmiston W. A., Smink R. D., Jr Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med. 1990 Oct 4;323(14):946–955. doi: 10.1056/NEJM199010043231404. [DOI] [PubMed] [Google Scholar]
  10. Burr M. L., Fehily A. M., Gilbert J. F., Rogers S., Holliday R. M., Sweetnam P. M., Elwood P. C., Deadman N. M. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757–761. doi: 10.1016/s0140-6736(89)90828-3. [DOI] [PubMed] [Google Scholar]
  11. Canner P. L., Berge K. G., Wenger N. K., Stamler J., Friedman L., Prineas R. J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–1255. doi: 10.1016/s0735-1097(86)80293-5. [DOI] [PubMed] [Google Scholar]
  12. Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223(5):405–418. doi: 10.1111/j.0954-6820.1988.tb15891.x. [DOI] [PubMed] [Google Scholar]
  13. Collins R., Keech A., Peto R., Sleight P., Kjekshus J., Wilhelmsen L., MacMahon S., Shaw J., Simes J., Braunwald E. Cholesterol and total mortality: need for larger trials. BMJ. 1992 Jun 27;304(6843):1689–1689. doi: 10.1136/bmj.304.6843.1689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Criqui M. H. Cholesterol, primary and secondary prevention, and all-cause mortality. Ann Intern Med. 1991 Dec 15;115(12):973–976. doi: 10.7326/0003-4819-115-12-973. [DOI] [PubMed] [Google Scholar]
  15. Davey Smith G., Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992 Feb 15;304(6824):431–434. doi: 10.1136/bmj.304.6824.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  17. Dewar H. A., Oliver M. F. Trial of clofibrate. Br Med J. 1972 Feb 19;1(5798):506–506. doi: 10.1136/bmj.1.5798.506-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dorr A. E., Gundersen K., Schneider J. C., Jr, Spencer T. W., Martin W. B. Colestipol hydrochloride in hypercholesterolemic patients--effect on serum cholesterol and mortality. J Chronic Dis. 1978 Jan;31(1):5–14. doi: 10.1016/0021-9681(78)90076-0. [DOI] [PubMed] [Google Scholar]
  19. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L. J., Ye C. Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8931–8934. doi: 10.1073/pnas.87.22.8931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Frantz I. D., Jr, Dawson E. A., Ashman P. L., Gatewood L. C., Bartsch G. E., Kuba K., Brewer E. R. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis. 1989 Jan-Feb;9(1):129–135. doi: 10.1161/01.atv.9.1.129. [DOI] [PubMed] [Google Scholar]
  21. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  22. Frick M. H., Heinonen O. P., Huttunen J. K., Koskinen P., Mänttäri M., Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993 Feb;25(1):41–45. doi: 10.3109/07853899309147855. [DOI] [PubMed] [Google Scholar]
  23. Goldstein M. R. Cholesterol inhibition, cancer, and coronary heart disease. Lancet. 1992 Jul 11;340(8811):127–128. doi: 10.1016/0140-6736(92)90461-b. [DOI] [PubMed] [Google Scholar]
  24. Green K. G., Heady A., Oliver M. F. Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate. Int J Epidemiol. 1989 Jun;18(2):355–360. doi: 10.1093/ije/18.2.355. [DOI] [PubMed] [Google Scholar]
  25. Gross L., Figueredo R. Long-term cholesterol-lowering effect of colestipol resin in humans. J Am Geriatr Soc. 1973 Dec;21(12):552–556. doi: 10.1111/j.1532-5415.1973.tb01662.x. [DOI] [PubMed] [Google Scholar]
  26. Harrold B. P., Marmion V. J., Gough K. R. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes. 1969 May;18(5):285–291. doi: 10.2337/diab.18.5.285. [DOI] [PubMed] [Google Scholar]
  27. Heady J. A., Morris J. N., Oliver M. F. WHO clofibrate/cholesterol trial: clarifications. Lancet. 1992 Dec 5;340(8832):1405–1406. doi: 10.1016/0140-6736(92)92588-7. [DOI] [PubMed] [Google Scholar]
  28. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990 Dec;82(6):1916–1924. doi: 10.1161/01.cir.82.6.1916. [DOI] [PubMed] [Google Scholar]
  29. Houtsmuller A. J. Treatment of exudative diabetic retinopathy with atromid-S. Ophthalmologica. 1968;156(1):2–5. doi: 10.1159/000305357. [DOI] [PubMed] [Google Scholar]
  30. Isles C. G., Hole D. J., Hawthorne V. M., Lever A. F. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet. 1992 Mar 21;339(8795):702–706. doi: 10.1016/0140-6736(92)90599-x. [DOI] [PubMed] [Google Scholar]
  31. Kane J. P., Malloy M. J., Ports T. A., Phillips N. R., Diehl J. C., Havel R. J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990 Dec 19;264(23):3007–3012. [PubMed] [Google Scholar]
  32. Lau J., Antman E. M., Jimenez-Silva J., Kupelnick B., Mosteller F., Chalmers T. C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992 Jul 23;327(4):248–254. doi: 10.1056/NEJM199207233270406. [DOI] [PubMed] [Google Scholar]
  33. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. Acta Med Scand Suppl. 1966;466:1–92. [PubMed] [Google Scholar]
  34. MARMORSTON J., MOORE F. J., HOPKINS C. E., KUZMA O. T., WEINER J. Clinical studies of long-term estrogen therapy in men with mvocardial infarction. Proc Soc Exp Biol Med. 1962 Jun;110:400–408. doi: 10.3181/00379727-110-27531. [DOI] [PubMed] [Google Scholar]
  35. MacMahon S. Lowering cholesterol: effects on trauma death, cancer death and total mortality. Aust N Z J Med. 1992 Oct;22(5 Suppl):580–582. doi: 10.1111/j.1445-5994.1992.tb00481.x. [DOI] [PubMed] [Google Scholar]
  36. Manolio T. A., Ettinger W. H., Tracy R. P., Kuller L. H., Borhani N. O., Lynch J. C., Fried L. P. Epidemiology of low cholesterol levels in older adults. The Cardiovascular Health Study. Circulation. 1993 Mar;87(3):728–737. doi: 10.1161/01.cir.87.3.728. [DOI] [PubMed] [Google Scholar]
  37. McCaughan D. The long-term effects of probucol on serum lipid levels. Arch Intern Med. 1981 Oct;141(11):1428–1432. [PubMed] [Google Scholar]
  38. McIsaac W. J., Naylor C. D., Basinski A. Mismatch of coronary risk and treatment intensity under the National Cholesterol Education Program guidelines. J Gen Intern Med. 1991 Nov-Dec;6(6):518–523. doi: 10.1007/BF02598220. [DOI] [PubMed] [Google Scholar]
  39. Muldoon M. F., Manuck S. B., Matthews K. A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990 Aug 11;301(6747):309–314. doi: 10.1136/bmj.301.6747.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Neaton J. D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992 Jan;152(1):56–64. [PubMed] [Google Scholar]
  41. OLIVER M. F., BOYD G. S. Influence of reduction of serum lipids on prognosis of coronary heart-disease. A five-year study using oestrogen. Lancet. 1961 Sep 2;2(7201):499–505. doi: 10.1016/s0140-6736(61)92951-8. [DOI] [PubMed] [Google Scholar]
  42. Oliver M. F. Doubts about preventing coronary heart disease. BMJ. 1992 Feb 15;304(6824):393–394. doi: 10.1136/bmj.304.6824.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ornish D., Brown S. E., Scherwitz L. W., Billings J. H., Armstrong W. T., Ports T. A., McLanahan S. M., Kirkeeide R. L., Brand R. J., Gould K. L. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990 Jul 21;336(8708):129–133. doi: 10.1016/0140-6736(90)91656-u. [DOI] [PubMed] [Google Scholar]
  44. Pearce M. L., Dayton S. Incidence of cancer in men on a diet high in polyunsaturated fat. Lancet. 1971 Mar 6;1(7697):464–467. doi: 10.1016/s0140-6736(71)91086-5. [DOI] [PubMed] [Google Scholar]
  45. ROSE G. A., THOMSON W. B., WILLIAMS R. T. CORN OIL IN TREATMENT OF ISCHAEMIC HEART DISEASE. Br Med J. 1965 Jun 12;1(5449):1531–1533. doi: 10.1136/bmj.1.5449.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ramsay L. E., Yeo W. W., Jackson P. R. Dietary reduction of serum cholesterol concentration: time to think again. BMJ. 1991 Oct 19;303(6808):953–957. doi: 10.1136/bmj.303.6808.953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992 Jul 4;305(6844):15–19. doi: 10.1136/bmj.305.6844.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Rogers M. C. Sir John Scott Burdon-Sanderson (1828-1905): a pioneer in electrophysiology. Circulation. 1969 Jul;40(1):1–2. doi: 10.1161/01.cir.40.1.1. [DOI] [PubMed] [Google Scholar]
  49. Rossouw J. E., Lewis B., Rifkind B. M. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990 Oct 18;323(16):1112–1119. doi: 10.1056/NEJM199010183231606. [DOI] [PubMed] [Google Scholar]
  50. STAMLER J., PICK R., KATZ L. N., PICK A., KAPLAN B. M., BERKSON D. M., CENTURY D. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA. 1963 Feb 23;183:632–638. doi: 10.1001/jama.1963.03700080040013. [DOI] [PubMed] [Google Scholar]
  51. Sahni R., Maniet A. R., Voci G., Banka V. S. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J. 1991 Jun;121(6 Pt 1):1600–1608. doi: 10.1016/0002-8703(91)90002-y. [DOI] [PubMed] [Google Scholar]
  52. Schmidt J. G. Cholesterol lowering treatment and mortality. BMJ. 1992 Nov 14;305(6863):1226–1227. doi: 10.1136/bmj.305.6863.1226-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Sheldon T. A., Smith G. D. Consensus conferences as drug promotion. Lancet. 1993 Jan 9;341(8837):100–102. doi: 10.1016/0140-6736(93)92569-f. [DOI] [PubMed] [Google Scholar]
  54. Silberberg J. S., Henry D. A. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1. A meta-analysis of cholesterol-lowering trials. Med J Aust. 1991 Nov 18;155(10):665-6, 669-70. [PubMed] [Google Scholar]
  55. Singh R. B., Rastogi S. S., Verma R., Laxmi B., Singh R., Ghosh S., Niaz M. A. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ. 1992 Apr 18;304(6833):1015–1019. doi: 10.1136/bmj.304.6833.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Smith G. D., Pekkanen J. The cholesterol controversy. BMJ. 1992 Apr 4;304(6831):913–913. doi: 10.1136/bmj.304.6831.913-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Smith G. D., Shipley M. J., Marmot M. G., Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA. 1992 Jan 1;267(1):70–76. [PubMed] [Google Scholar]
  58. Smith W. C., Tunstall-Pedoe H., Crombie I. K., Tavendale R. Concomitants of excess coronary deaths--major risk factor and lifestyle findings from 10,359 men and women in the Scottish Heart Health Study. Scott Med J. 1989 Dec;34(6):550–555. doi: 10.1177/003693308903400603. [DOI] [PubMed] [Google Scholar]
  59. Tobert J. A. The cholesterol controversy. BMJ. 1992 Mar 14;304(6828):713–713. doi: 10.1136/bmj.304.6828.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Watts G. F., Lewis B., Brunt J. N., Lewis E. S., Coltart D. J., Smith L. D., Mann J. I., Swan A. V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet. 1992 Mar 7;339(8793):563–569. doi: 10.1016/0140-6736(92)90863-x. [DOI] [PubMed] [Google Scholar]
  61. Woodhill J. M., Palmer A. J., Leelarthaepin B., McGilchrist C., Blacket R. B. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol. 1978;109:317–330. doi: 10.1007/978-1-4684-0967-3_18. [DOI] [PubMed] [Google Scholar]
  62. de Bont A. J., Baker I. A., St Leger A. S., Sweetnam P. M., Wragg K. G., Stephens S. M., Hayes T. M. A randomised controlled trial of the effect of low fat diet advice on dietary response in insulin independent diabetic women. Diabetologia. 1981 Dec;21(6):529–533. doi: 10.1007/BF00281543. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES